STOCK TITAN
  1. Home
  2. News
  3. LGND

Ligand Pharmaceuticals Inc. - LGND STOCK NEWS

Welcome to our dedicated page for Ligand Pharmaceuticals news (Ticker: LGND), a resource for investors and traders seeking the latest updates and insights on Ligand Pharmaceuticals stock.

Ligand Pharmaceuticals Inc. (symbol: LGND) is a prominent biopharmaceutical company committed to advancing healthcare through innovative technologies and strategic partnerships. The company focuses on developing and acquiring assets that support the creation and commercialization of medicine. Ligand operates with a streamlined cost structure to maximize cash flow and enhance shareholder returns.

The company’s revenue is derived from three primary sources: royalties from commercialized products, license and milestone payments, and the sale of its proprietary Captisol material. Captisol is a chemically modified cyclodextrin that enhances the solubility and stability of drugs.

Ligand has a diverse portfolio of commercial and near-term revenue-generating assets. Its business model includes drug discovery, early-stage drug development, product reformulation, and alliances with other pharmaceutical and biotechnology companies. These partnerships and license agreements are crucial for the company’s long-term financial growth.

Recently, Ligand has made significant strides in its ongoing projects and collaborations. The company continues to build a robust pipeline with an emphasis on innovation and operational efficiency. Investors and stakeholders can expect regular updates on the company’s performance, new agreements, and advancements in drug development.

With a commitment to delivering meaningful returns and improving global health outcomes, Ligand Pharmaceuticals remains a key player in the biopharmaceutical industry. Stay informed about the latest news and developments by following Ligand's journey and updates.

News

Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Ligand Pharmaceuticals (LGND) granted non-qualified stock option awards to two non-executive employees, totaling 93,700 shares, 32,750 restricted stock units, and 40,000 performance stock units. The options have an exercise price of $74.17 per share and will vest over four years. RSUs will vest over three years, and PSUs will vest based on company performance objectives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
none
-
News

U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum

Rhea-AI Summary
Ligand Pharmaceuticals Incorporated (LGND) announced FDA approval of ZELSUVMI™ (berdazimer topical gel, 10.3%) for the treatment of molluscum contagiosum in adults and pediatric patients. ZELSUVMI is the first novel drug for this treatment and the first and only topical prescription medication that can be applied by patients, parents, or caregivers at home. It is expected to be commercially available in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.97%
Tags
fda approval
-
News

Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance

Rhea-AI Summary
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) hosted an Investor and Analyst Day in New York City to provide an overview of the company’s business model, investment selection process, 2024 guidance, and portfolio progress. Ligand focuses on investing in late-clinical stage assets and licensing the Captisol® technology platform to generate revenues for shareholders. The company has undergone a restructuring to focus on a lean infrastructure and high-margin business. Management highlighted late-stage assets and potential pipeline events in 2024, along with recent transactions, the Captisol Technology Platform, and the 2024 investment outlook.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
none
News

Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City

Rhea-AI Summary
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host its Investor and Analyst Day on Tuesday, December 12, 2023. The event will provide an update on the company’s strategy, portfolio, multi-year financial outlook, and a 2024 guidance preview. The in-person event will be held at the Harvard Club in New York City, with a live and archived webcast available for remote viewing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.73%
Tags
conferences
-
News

OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights

Rhea-AI Summary
OmniAb, Inc. (NASDAQ: OABI) reported Q3 2023 financial results, highlighting a $5.5 million revenue and $15.7 million net loss. The company's partner portfolio grew to 314 active programs, up from 291 at the beginning of the year. OmniAb also announced a Research & Technology Virtual Event showcasing their new OmnidAb™ technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.61%
Tags
earnings
-
News

Ligand Acquires Royalty on Sanofi’s TZIELD® for $20 Million

Rhea-AI Summary
Ligand Pharmaceuticals has acquired Tolerance Therapeutics for $20 million in cash. Tolerance Therapeutics is the owner of TZIELD, the first FDA approved treatment to delay the onset of Stage 3 type 1 diabetes. TZIELD is marketed by Sanofi, and recent data from its Phase 3 trial showed its potential to slow the progression of Stage 3 T1D in children and adolescents. Ligand CEO Todd C. Davis sees TZIELD as a valuable addition to their portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
acquisition
News

Ligand To Report Third Quarter 2023 Financial Results On November 8

Rhea-AI Summary
Ligand Pharmaceuticals will report Q3 2023 financial results and hold a conference call on November 8, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
conferences earnings
-
News

Ligand Acquires Assets of Novan, Inc. for $12.2 Million

Rhea-AI Summary
Ligand Pharmaceuticals has closed the acquisition of Novan's assets for $15 million, including berdazimer gel and NITRICIL technology. The remaining assets of EPI Health will be sold to other parties. Berdazimer gel is on track for FDA approval as the first at-home treatment for molluscum contagiosum. Ligand plans to seek marketing partners to maximize value for shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.09%
Tags
acquisition
-
News

Ligand Appoints Martine Zimmermann to its Board of Directors

Rhea-AI Summary
Ligand Pharmaceuticals appoints Martine Zimmermann as independent director, bringing 25 years of global pharmaceutical industry experience. Her expertise in development and regulatory affairs will be valuable as Ligand builds its partnered programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.09%
Tags
management
News

Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio

Rhea-AI Summary
Ligand retains Pelican commercial royalties and owns 49.9% of Primrose Bio. Ligand contributes $15M for economic interest in Primrose programs. Ligand improves cash expense outlook and raises EPS guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
acquisition

FAQ

What is the current stock price of Ligand Pharmaceuticals (LGND)?

The current stock price of Ligand Pharmaceuticals (LGND) is $110.31 as of January 7, 2025.

What is the market cap of Ligand Pharmaceuticals (LGND)?

The market cap of Ligand Pharmaceuticals (LGND) is approximately 2.1B.

What does Ligand Pharmaceuticals Inc. do?

Ligand Pharmaceuticals Inc. develops and acquires technologies that aid in creating medicine, focusing on drug discovery, early-stage drug development, product reformulation, and partnerships.

What are the primary sources of revenue for Ligand?

Ligand’s revenue primarily comes from royalties from commercialized products, license and milestone payments, and the sale of its proprietary Captisol material.

What is Captisol?

Captisol is a modified cyclodextrin used to improve the solubility and stability of drugs, contributing significantly to Ligand's revenue stream.

How does Ligand aim to maximize shareholder returns?

Ligand maximizes shareholder returns by operating on a lean cost structure, focusing on commercial and near-term revenue-generating assets to enhance cash flow.

What is Ligand’s business model?

Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and forming strategic partnerships with pharmaceutical and biotechnology companies.

Who are Ligand’s partners?

Ligand has partnerships and license agreements with various pharmaceutical and biotechnology companies, leveraging their collaborations for mutual growth.

What recent achievements has Ligand made?

Ligand has made significant advancements in its projects and collaborations, building a strong pipeline centered on innovation and operational efficiency.

How does Ligand maintain its operations cost-effectively?

Ligand maintains cost-effective operations by using a streamlined cost structure that enhances cash flow and focuses on strategic investments.

What can investors expect from Ligand in the future?

Investors can expect continuous updates on the company’s performance, new agreements, and progress in drug development, contributing to long-term financial growth.

How can I stay informed about Ligand's latest news?

You can stay informed about Ligand’s latest news and developments by following their updates and announcements regularly.
Stock LGND logo
Ligand Pharmaceuticals Inc.

Nasdaq:LGND

LGND Rankings

#1954 Ranked by Market Cap
N/A Ranked by Dividends

LGND Stock Data

2.05B
18.54M
1.88%
100.63%
4.3%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO